Biogen logo

Biogen

BIIB | NASDAQ
Chart Builder DCF Calculator
$251.65
-$1.75 (-0.69%)
At close: Nov 16, 2026, 4:00 PM ET
$251.65
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-0.69%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
32.4
-0.2 pts
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #737/1021 (Top 72%)

Key Statistics

Market Data

Market Cap $37.2B
1D Range
250.91 255.42
52W Range
164.42 255.42

Valuation (TTM)

PE 107.54
PB 1.97
EV/EBITDA 30.16

Valuation (NTM)

Forward PE 20.27
Forward PEG -6.58
Price Target $257.00
Loading financial charts...

Profile

Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its establish...

Sector Healthcare
Employees 7,500
IPO Date Sep 17, 1991
Fiscal Year January - December

Latest News

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026

7 hours ago · prnewswire.com

New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease

20 hours ago · businesswire.com

TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative Disease
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's Disease

4 days ago · globenewswire.com

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer's Disease
Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs

6 days ago · 247wallst.com

Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs
These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results

19 days ago · benzinga.com

These Analysts Increase Their Forecasts On Biogen After Upbeat Q3 Results
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026

19 days ago · globenewswire.com

Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Biogen Q3 Earnings Call Highlights

19 days ago · marketbeat.com

Biogen Q3 Earnings Call Highlights
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript

19 days ago · seekingalpha.com

Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened

19 days ago · zacks.com

BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Big Day for Econ Data, Hyperscaler Earnings

20 days ago · zacks.com

Big Day for Econ Data, Hyperscaler Earnings

Earnings

Latest Earnings
Oct 28, 2026
EPS
$2.62
Beat +31.66%
REV
$2.8B
Beat +6.43%
Next Earnings
Feb 5, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
24
Consensus
Buy
Price Target
$257.00
Upside
+2.13%
Buy (16)
Hold (7)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.